Intellipharmaceutics inc
Nettet6. jun. 2024 · Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral ... Nettet7. mar. 2024 · Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic …
Intellipharmaceutics inc
Did you know?
NettetINTELLIPHARMACEUTICS INTERNATIONAL INC. : Kurs Aktie Börse A2N5Y4 CA4581733090 MarketScreener Startseite Aktien Kanada Toronto Stock Exchange Intellipharmaceutics International Inc. Übersicht IPCI CA4581733090 INTELLIPHARMACEUTICS INTERNATIONAL INC. (A2N5Y4) Zur Watchlist … Nettet4. apr. 2024 · Intellipharmaceutics International Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of …
NettetTORONTO (AP) _ Intellipharmaceutics International Inc. (IPCIF) on Friday reported a loss of $296,000 in its fiscal third quarter. On a per-share basis, the Toronto -based company said it had a loss of 1 cent. The extended-release drug developer posted revenue of $19,100 in the period. Its adjusted revenue was $19,000. Nettet21. jul. 2024 · TORONTO, ON / ACCESSWIRE / July 21, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in...
Nettet21. jul. 2024 · Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.
Nettet14. apr. 2024 · Intellipharmaceutics International Inc. a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2024.
Nettet7. mar. 2024 · Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral... buckley christopher lawNettet2. jul. 2024 · Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. credit scores and creditNettet13. okt. 2024 · Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release oral solid... buckley cia station chiefNettet1. apr. 2024 · Intellipharmaceutics International Inc. (IPCIF) SEC Filing 20-F Annual Report for the fiscal year ending Monday, November 30, 2024. Home. SEC Filings. Intellipharmaceutics International Inc. (IPCIF) 20-F Annual Report Fri Apr 01 2024. 20-F Annual Report 20-F YoY Changes. buckley christopher p.cNettet2. jul. 2024 · Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral... buckley churchesNettet1. mar. 2024 · TORONTO (AP) _ Intellipharmaceutics International Inc. (IPCIF) on Monday reported a loss of $2 million in its fiscal fourth quarter. The Toronto-based company said it had a loss of 17 cents per share. For the year, the company reported that its loss widened to $5.1 million, or 17 cents per share. _____ credit score safe websiteNettet19. mar. 2013 · Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral... buckley christopher